Self-guided Treatment for Adolescents Navigating Depression

Sponsor
Limbix Health, Inc. (Industry)
Overall Status
Recruiting
CT.gov ID
NCT05462652
Collaborator
(none)
220
1
2
11.1
19.8

Study Details

Study Description

Brief Summary

The goal of this study is to test whether an investigational mobile app can be a helpful treatment option for adolescents with symptoms of depression. Adolescents aged 13 to 21 with depression symptoms can be part of this study if eligible.

Eligible participants will be randomly assigned to one of two groups: one group will receive the mobile app intervention in addition to their usual care and the other group will simply continue their usual care for symptoms of depression. Both groups will have 5 weeks to use a study app.

Condition or Disease Intervention/Treatment Phase
  • Device: Active Intervention
N/A

Detailed Description

The primary aim of the proposed research is to evaluate the effectiveness of a self-guided, cognitive behavioral therapy (CBT)-based mobile app + assessment-enhanced Usual Care (eUC) compared to eUC alone as an intervention for adolescents with symptoms of depression who are under the supervision of a licensed healthcare provider.

The sample size for this study is 220 subjects. Sample size calculation is based on primary outcome patient health questionnaire (PHQ-8) at post-intervention. Six PHQ-8 measurements will be collected from each subject (baseline and weekly during the 5-week intervention period). Using a two-sample t-test approach, assuming a two-tailed alpha set at 0.05, a total of 200 participants (100 in each study arm) will give us 80% power to detect a moderate effect size of at least d=0.4. Given an anticipated 10% rate of attrition, we aim to enroll 220 total participants in the study.

A 50% female sample will be targeted. Earlier recruitment efforts within the study demographic have resulted in majority female samples, consistent with prevalence rates within the study population. As such, recruitment efforts will be undertaken to ensure representation of male participants. Recruitment efforts will be taken to ensure adequate representation of underrepresented racial and ethnic minority groups.

Children between the ages of 13-17 will be included in this research as the program to be evaluated is specifically designed as an intervention for adolescents with symptoms of depression. Assent will be obtained from all children under 18 for study enrollment unless legally emancipated or financially independent in accordance with CA state regulations and regulations of the state in which the minor resides.

Description of the mobile app intervention program:

The intervention is a 5-week program divided into 5 levels intended to be completed weekly. Each level is expected to take about 60 minutes to complete. Activities in each level may include reading text on the screen, answering multiple choice style questions, swiping or clicking a button to move through screens, dragging and dropping elements on screen, and completing tasks outside of the app. Certain on-demand resources can be accessed in the apps at any time, including crisis resources. Where appropriate, text entries in the app that match a database of concerning words/phrases will trigger an automated pop-up suggesting participants visit the in-app crisis resources if they need additional support. Participants will be instructed to complete a weekly PHQ-8 assessment in the mobile app

Description of assessment-enhanced Usual Care (eUC):

UC is based on a stepped care model for treatment for symptoms of depression. It can include any of the following: active monitoring of depressive symptoms and suicidality, supportive counseling by a healthcare provider, psychosocial support interventions, collaborative care (e.g. facilitation of parental and patient self-management, referral for peer support or other community or school-based behavioral health programs), psychoeducation, complementary and alternative medicine approaches, psychotherapy (e.g. behavioral treatment, interpersonal therapy, cognitive behavioral therapy), pharmacotherapy for mood problems, visit to a primary care provider, behavioral or mental health specialist or therapist, counselor or coach for mood disorder. For purposes of this study, UC will be enhanced by prompting participants to complete weekly PHQ-8 and PSC assessments in a mobile app. Study staff will monitor participants' symptom deterioration and questionnaire data for safety.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
220 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Investigator)
Primary Purpose:
Treatment
Official Title:
Project STAND (Self-guided Treatment for Adolescents Navigating Depression): a Randomized Controlled Trial
Actual Study Start Date :
Jul 28, 2022
Anticipated Primary Completion Date :
Dec 1, 2022
Anticipated Study Completion Date :
Jul 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Active Intervention

The active intervention is a 5-week program divided into 5 levels intended to be completed weekly. Each level is expected to take about 60 minutes to complete. Activities in each level may include reading text on the screen, answering multiple choice style questions, swiping or clicking a button to move through screens, dragging and dropping elements on screen, and completing tasks outside of the app. Certain on-demand resources can be accessed in the apps at any time, including crisis resources. Where appropriate, text entries in the app that match a database of concerning words/phrases will trigger an automated pop-up suggesting participants visit the in-app crisis resources if they need additional support. Participants will be instructed to complete a weekly PHQ-8 assessment in the mobile app.

Device: Active Intervention
The active intervention is a 5-week program divided into 5 levels intended to be completed weekly. Each level is expected to take about 60 minutes to complete. Activities in each level may include reading text on the screen, answering multiple choice style questions, swiping or clicking a button to move through screens, dragging and dropping elements on screen, and completing tasks outside of the app. Certain on-demand resources can be accessed in the apps at any time, including crisis resources. Where appropriate, text entries in the app that match a database of concerning words/phrases will trigger an automated pop-up suggesting participants visit the in-app crisis resources if they need additional support. Participants will be instructed to complete a weekly PHQ-8 assessment in the mobile app.

No Intervention: Usual Care

UC is based on a stepped care model for treatment for symptoms of depression. It can include any of the following: active monitoring of depressive symptoms and suicidality, supportive counseling by a healthcare provider, psychosocial support interventions, collaborative care (e.g. facilitation of parental and patient self-management, referral for peer support or other community or school-based behavioral health programs), psychoeducation, complementary and alternative medicine approaches, psychotherapy (e.g. behavioral treatment, interpersonal therapy, cognitive behavioral therapy), pharmacotherapy for mood problems, visit to a primary care provider, behavioral or mental health specialist or therapist, counselor or coach for mood disorder. For purposes of this study, UC will be enhanced by prompting participants to complete weekly PHQ-8 and PSC assessments in a mobile app. Study staff will monitor participants' symptom deterioration and questionnaire data for safety.

Outcome Measures

Primary Outcome Measures

  1. Depressive symptom severity [5 weeks]

    Measured by the Patient Health Questionnaire (PHQ-8) an 8-item participant-report measure for screening for depression and for establishing depression severity. The total score ranges from 0-24, with a higher score indicating greater depression symptom severity.

Secondary Outcome Measures

  1. Intervention response at post intervention [Change from baseline to post intervention (5 weeks)]

    Measured by the Patient Health Questionnaire (PHQ-8) an 8-item participant-report measure for screening for depression and for establishing depression severity. The total score ranges from 0-24, with a higher score indicating greater depression symptom severity. Intervention response is defined as a 50% reduction in PHQ-8 score from baseline.

  2. Remission at post intervention (PHQ-8 score <5) [Time Frame: post intervention (5 weeks)]

    Measured by the Patient Health Questionnaire (PHQ-8) an 8-item participant-report measure for screening for depression and for establishing depression severity. The total score ranges from 0-24, with a higher score indicating greater depression symptom severity. Remission is defined as a PHQ-8 score less than 5 at post-intervention

Eligibility Criteria

Criteria

Ages Eligible for Study:
13 Years to 21 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • 13-21 years of age

  • PHQ-8 score ≥ 5 at eligibility screening

  • English fluency and literacy (participant and legal guardian, if applicable)

  • Access to a compatible smartphone (or other device) and operating system (i.e., capable of installing the app from the Google Play or Apple App Store; list will be provided on study website and regular internet access

  • Participant willing and able to provide informed consent/assent and have legal guardian willing and able to provide informed consent (if required)

  • Under the care of a licensed healthcare provider and willing to provide contact information for the provider and sign a HIPAA release that allows Limbix to contact provider

  • Willing and able to provide information required for study enrollment (e.g. all responses to initial PHQ-8 assessment, and current antidepressant medication status)

Exclusion Criteria:
  • Diagnosis of (or treatment for) bipolar disorder, post traumatic stress disorder, psychotic disorder, substance use disorder, or eating disorder within the 12 months prior to eligibility screening

  • Change in psychotropic medication (initiation or change in dose) within the 30 days prior to eligibility screening

  • Plans to initiate or change treatment (e.g., psychotherapy, psychotropic medication, and/or other psychosocial treatment) for a mental health disorder during the study intervention period (5 weeks) as determined at eligibility screening

  • Suicide attempt within the past year

  • Active suicide ideation with intent

  • Previous participation in user testing or clinical testing of Spark or SparkRx, or other previous use of SparkRx app

  • Participation in any other clinical research involving a mental health intervention or treatment within 60 days prior to eligibility screening

  • Plans to participate in any other clinical research involving a mental health intervention or treatment during the study intervention period (5 weeks) as determined at eligibility screening

  • Any condition, comorbidity, or event that, in the opinion of the investigator, will prevent the participant from adhering to the protocol or benefitting from the intervention (e.g., coercion, low level of cognitive functioning) or will prevent investigators from being able to ensure safety (e.g., will be leaving the country during study time period)

  • Having a sibling who is a past or current participant in the study

Contacts and Locations

Locations

Site City State Country Postal Code
1 Limbix Health, Inc. San Francisco California United States 94104

Sponsors and Collaborators

  • Limbix Health, Inc.

Investigators

  • Principal Investigator: Aarthi Padmanabhan, PhD, Limbix Health, Inc.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Limbix Health, Inc.
ClinicalTrials.gov Identifier:
NCT05462652
Other Study ID Numbers:
  • LMX-001
First Posted:
Jul 18, 2022
Last Update Posted:
Aug 12, 2022
Last Verified:
Aug 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Keywords provided by Limbix Health, Inc.
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 12, 2022